Drug intelligence / Profile preview

CAM2047

Development stage: Unknown
Lead developer: Camurus
Modality: Drug Delivery Systems, Small Molecules
Administration: Subcutaneous

Overview

CAM2047 is a long-acting subcutaneous depot formulation of granisetron, a 5-HT3 receptor antagonist, developed by Camurus for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug utilizes Camurus's proprietary FluidCrystal® injection depot technology, which allows for the sustained release of granisetron over an extended period. This formulation is designed to address both acute and delayed CINV, a common and debilitating side effect of chemotherapy. CAM2047 is administered as a subcutaneous injection and has completed Phase 1 clinical development, demonstrating its potential as a long-acting treatment option in oncology supportive care.

Other names: granisetron subcutaneous depotgranisetron FluidCrystal

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on CAM2047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAM2047.

Explore the full profile